|
³»¿ë |
ÁÂÀå/¿¬ÀÚ |
08:30~09:00 |
Registration |
09:00~09:10 |
Opening |
¼º¸¾ç(¿µ³²ÀÇ´ë) |
09:10~10:10
Symposium I :
Immune tolerance in solid organ transplantation |
ÁÂÀå:±è»óÁØ(¼¿ïÀÇ´ë),
±èÀ¯¼±(¿¬¼¼ÀÇ´ë) |
09:10~09:30 |
Monitoring of immune tolerance |
ÀÌ»óÈ£(°æÈñÀÇ´ë) |
09:30~09:50 |
Tolerance induction protocol in kidney transplantation |
¾çÀç¼®(¼¿ïÀÇ´ë) |
09:50~10:10 |
Tolerance induction protocol in liver transplantation |
À¯Èñö(ÀüºÏÀÇ´ë) |
10:10~10:40 |
Coffee Break |
10:40~12:00
Symposium II :
Issue about live organ donor |
ÁÂÀå:ÇÑ´öÁ¾(¿ï»êÀÇ´ë),
ä±Ç¹¬(¿ø±¤ÀÇ´ë) |
10:40~11:00 |
»ýü±âÁõÀÚÀÇ ¼úÈÄ ÇÕº´Áõ (½ÅÀå°ú °£) |
Á¤»ó¿µ(Àü³²ÀÇ´ë) |
11:00~11:20 |
»ýü±âÁõÀÚÀÇ Á¤½ÅÀû ½ºÆ®·¹½º |
À±ÀÍÁø(°Ç±¹ÀÇ´ë) |
11:20~11:40 |
»ýü±âÁõÀÚ¿¡ ´ëÇÑ ¼úÀü ±³À° ¹× ¼úÈÄ °ü¸® ÇÁ·Î±×·¥ |
º¯³âÀÓ(¼¿ï´ëº´¿ø) |
11:40~12:00 |
Panel Discussion |
12:00~12:25
Symposium III:
KSOT Report |
ÁÂÀå:°Á¾¸í(ÇѾçÀÇ´ë),
±èµ¿±¸(°¡Å縯ÀÇ´ë) |
12:00~12:10 |
CAST °á»êº¸°í |
±èÀ¯¼±(¿¬¼¼ÀÇ´ë) |
12:10~12:25 |
Àå±âÀ̽ĵî·Ï ½Ã¹ü»ç¾÷ |
±è¸í±Ô(¼¿ïÀÇ´ë) |
Concurrent Symposium I |
14:00~15:20
Concurrent Symposium I (Kidney 1)
Cardiovascular disease and
kidney transplantation |
ÁÂÀå:¹Ú¼º±¤(ÀüºÏÀÇ´ë),
¾È±Ô¸®(¼¿ïÀÇ´ë) |
14:00~14:20 |
Obesity and cardiovascular mortality |
Çã¿ì¼º(¼º±Õ°üÀÇ´ë) |
14:20- 14:40 |
Pre and post-op care in severely atherosclerotic patients |
±èÇüÅÂ(°è¸íÀÇ´ë) |
14:40~15:00 |
Cardiac evaluation before KT in ESRD patients |
Çã±ÔÇÏ(¿¬¼¼ÀÇ´ë) |
15:00~15:20 |
Lipid lowering agent in kidney transplantation |
½Åº´Ã¶(Á¶¼±ÀÇ´ë) |
14:00~15:20
Concurrent Symposium I (Liver 1)
Current status of DDLT
|
ÁÂÀå:À̼®±¸(¼º±Õ°üÀÇ´ë),
¼°æ¼®(¼¿ïÀÇ´ë) |
14:00-14:40 |
Split liver transplantation |
|
14:00~14:20 |
Outcome |
¼Û±â¿ø(¿ï»êÀÇ´ë) |
14:20~14:40 |
Optimal regulation of allocation |
À̱¤¿õ(¼¿ïÀÇ´ë) |
14:40~15:00 |
Marginal donor |
ÇÑ¿µ¼®(´ë±¸°¡Å縯) |
15:00~15:20 |
Discussion |
Ȳ½Å(¿ï»êÀÇ´ë),
À¯¿µ°æ(°¡Å縯ÀÇ´ë) |
14:00~15:20
Concurrent Symposium I:
Advances in immunologic test
|
ÁÂÀå:±èº´Ã¢(¸Þ¸®³îº´¿ø),
¼Òº´ÁØ(¿ø±¤ÀÇ´ë) |
14:00~14:20 |
PRA and donor-specific HLA antibody |
¹Ú¸íÈñ(¼¿ïÀÇ´ë) |
14:20~14:40 |
Detection of Anti-endothelial cell antibody |
°Àº¼÷(¼º±Õ°üÀÇ´ë) |
14:40~15:00 |
Method to detect cellular immune responses |
¿ÀÀºÁö(°¡Å縯ÀÇ´ë) |
15:00~15:20 |
Flow cytometry to measure the level of HLA or ABO antibodies |
¿øµ¿ÀÏ(°æºÏÀÇ´ë) |
15:20~15:40 |
Coffee Break |
Concurrent Symposium II |
15:40~17:00
Concurrent Symposium II (Kidney 2)
HBV infection in transplantation
|
ÁÂÀå:±è¼ºÈ¯(Á¶¼±ÀÇ´ë),
¾çö¿ì(°¡Å縯ÀÇ´ë) |
15:40~16:00 |
Impact of anti-viral tx. on long-term outcome |
Á¤º´ÇÏ(°¡Å縯ÀÇ´ë) |
16:00~16:20 |
Salvage therapy in lamivudine resistance |
±èÂù´ö(°æºÏÀÇ´ë) |
16:20~16:40 |
Immunosuppressive strategy in HBV (+) patients |
ÀÌ ½Ä(ÀüºÏÀÇ´ë) |
16:40~17:00 |
Use of HBV (+) donors |
ÃÖ¼öÁø³ª(Àü³²ÀÇ´ë) |
15:40~17:00
Concurrent Symposium II (Liver 2)
When to delist the patients
|
ÁÂÀå:±è¼øÀÏ(¿¬¼¼ÀÇ´ë),
Á¶Àç¿ø(¼º±Õ°üÀÇ´ë) |
15:40~16:00 |
HCC |
ÃÖ±âÈ«(¿¬¼¼ÀÇ´ë) |
16:00~16:20 |
Acute on chronic / fulminant hepatic failure |
ÀÓ¿µ (¿ï»êÀÇ´ë) |
16:20~16:40 |
Cardiopulmonary criteria |
ÃÖ¿ë¼±(¿¬¼¼ÀÇ´ë) |
16:40~17:00 |
Infectious status |
±è»óÀÏ(°¡Å縯ÀÇ´ë) |
15:40~17:00
Concurrent Symposium II
(Coordinator Session)
|
ÁÂÀå:ÇÏÈñ¼±(¼¿ï¾Æ»êº´¿ø),
±èº¹³à(»ï¼º¼¿ïº´¿ø) |
15:40~16:00 |
Overview of the MELD and PELD score |
ÁÖµ¿Áø(¿¬¼¼ÀÇ´ë) |
16:00~16:20 |
Pitfalls of emergency status 2A in LT |
Àü°æ¿Á(¼¼ºê¶õ½ºº´¿ø) |
16:20~16:40 |
Role of KODA for deceased donors |
º¹ÃáÈñ(Çѱ¹Àå±â±âÁõ¿ø) |
16:40~17:00 |
ÄÚµð³×ÀÌÅÍ ÃÑȸ |